We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Costco Wholesale Corp. (COST - Free Report) and Advanced Micro Devices, Inc. (AMD - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Visa, UnitedHealth and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., UnitedHealth Group Inc. and Eli Lilly and Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Visa shares have outperformed the Zacks Financial Transaction Services industry over the past year (+18.4% vs. +13.1%). Company's numerous buyouts and alliances paved the way for long-term growth and consistently drove its revenues.
Constant investments in technology are solidifying its position in the payments market. Higher cross-border volumes are boosting the company's results. A shift in payments to the digital mode is a boon for Visa. Steady domestic volumes and transactions rise will aid the firm to boost its top line in the future. A strong cash position enables it to boost shareholder value.
However, high operating expenses stress its margins. Ramped-up client incentives will dent the top line. Its volumes are likely to see diminishing effects of the Russia-Ukraine conflict. As such, it warrants a cautious stance.
Shares of UnitedHealth have declined -4.7% over the past six months against the Zacks Medical - HMOs industry's decline of -5.1%. The company's membership in its global business continues to decline. High operating costs are hurting margins. As such, the stock warrants a cautious stance.
Nevertheless, UnitedHealth Group's top line remains well-poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. Its solid health services segment provides diversification benefits.
The Government business remains well-poised for growth. A sturdy balance sheet enables business investments and prudent deployment of capital. Things are likely to improve in the future.
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.8% vs. +7.3%). The company's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes and cancer drug Jaypirca already launched. Mounjaro sales are already benefiting from strong demand trends. However, the CRL for donanemab will probably delay the potential launch of the candidate.
Generic competition for several drugs, rising pricing pressure in the United States and some international markets are some top-line headwinds. Estimates have declined slightly ahead of Q2 results. Lilly has a mixed record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Costco Wholesale Corp. and Advanced Micro Devices, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices
For Immediate Release
Chicago, IL – July 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Visa Inc. (V - Free Report) , UnitedHealth Group Inc. (UNH - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Costco Wholesale Corp. (COST - Free Report) and Advanced Micro Devices, Inc. (AMD - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Visa, UnitedHealth and Eli Lilly
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., UnitedHealth Group Inc. and Eli Lilly and Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Visa shares have outperformed the Zacks Financial Transaction Services industry over the past year (+18.4% vs. +13.1%). Company's numerous buyouts and alliances paved the way for long-term growth and consistently drove its revenues.
Constant investments in technology are solidifying its position in the payments market. Higher cross-border volumes are boosting the company's results. A shift in payments to the digital mode is a boon for Visa. Steady domestic volumes and transactions rise will aid the firm to boost its top line in the future. A strong cash position enables it to boost shareholder value.
However, high operating expenses stress its margins. Ramped-up client incentives will dent the top line. Its volumes are likely to see diminishing effects of the Russia-Ukraine conflict. As such, it warrants a cautious stance.
(You can read the full research report on Visa here >>>)
Shares of UnitedHealth have declined -4.7% over the past six months against the Zacks Medical - HMOs industry's decline of -5.1%. The company's membership in its global business continues to decline. High operating costs are hurting margins. As such, the stock warrants a cautious stance.
Nevertheless, UnitedHealth Group's top line remains well-poised for growth on the back of a strong market position, new deals, renewed agreements and expansion of service offerings. Its solid health services segment provides diversification benefits.
The Government business remains well-poised for growth. A sturdy balance sheet enables business investments and prudent deployment of capital. Things are likely to improve in the future.
(You can read the full research report on United Health here >>>)
Eli Lilly shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+37.8% vs. +7.3%). The company's revenue growth is being driven by higher demand for drugs like Trulicity, Taltz and others. It is regularly adding promising new pipeline assets through business development deals.
Lilly expects to launch four new medicines by 2023 end with Mounjaro for type II diabetes and cancer drug Jaypirca already launched. Mounjaro sales are already benefiting from strong demand trends. However, the CRL for donanemab will probably delay the potential launch of the candidate.
Generic competition for several drugs, rising pricing pressure in the United States and some international markets are some top-line headwinds. Estimates have declined slightly ahead of Q2 results. Lilly has a mixed record of earnings surprises in the recent quarters.
(You can read the full research report on Eli Lilly here >>>)
Other noteworthy reports we are featuring today include Costco Wholesale Corp. and Advanced Micro Devices, Inc..
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.